AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -184.34 Million USD | -251.53% |
| 2023 | -52.44 Million USD | -97.54% |
| 2022 | -26.54 Million USD | 15.85% |
| 2021 | -31.54 Million USD | 80.97% |
| 2020 | -165.78 Million USD | -370.28% |
| 2019 | 61.34 Million USD | 275.51% |
| 2018 | 16.33 Million USD | 133.09% |
| 2017 | 7 Million USD | 115.77% |
| 2016 | -44.45 Million USD | -1260.19% |
| 2015 | -3.26 Million USD | -205.83% |
| 2014 | 3.08 Million USD | 602.93% |
| 2013 | -614 Thousand USD | 87.95% |
| 2012 | -5.09 Million USD | -161.93% |
| 2011 | 8.22 Million USD | -33.19% |
| 2010 | 12.31 Million USD | 23.96% |
| 2009 | 9.93 Million USD | -8.79% |
| 2008 | 10.88 Million USD | 219.31% |
| 2007 | -9.12 Million USD | -232.93% |
| 2006 | 6.86 Million USD | 50.97% |
| 2005 | 4.54 Million USD | 44.7% |
| 2004 | 3.14 Million USD | 165.01% |
| 2003 | 1.18 Million USD | 17.54% |
| 2002 | 1 Million USD | 194.17% |
| 2001 | 343 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 45.88 Million USD | 313.74% |
| 2024 Q3 | -187.73 Million USD | -546.3% |
| 2024 FY | -184.34 Million USD | -251.53% |
| 2024 Q4 | -13.44 Million USD | 92.84% |
| 2024 Q2 | -29.04 Million USD | -163.31% |
| 2023 Q1 | -13 Million USD | -107.53% |
| 2023 Q2 | -8.48 Million USD | 34.74% |
| 2023 Q3 | -9.48 Million USD | -11.77% |
| 2023 Q4 | -21.46 Million USD | -126.33% |
| 2023 FY | -52.44 Million USD | -97.54% |
| 2022 FY | -26.54 Million USD | 15.85% |
| 2022 Q4 | -6.26 Million USD | -26.38% |
| 2022 Q3 | -4.95 Million USD | 40.63% |
| 2022 Q2 | -8.35 Million USD | -19.78% |
| 2022 Q1 | -6.97 Million USD | 64.19% |
| 2021 Q4 | -19.46 Million USD | -449.32% |
| 2021 Q3 | -3.54 Million USD | 16.96% |
| 2021 FY | -31.54 Million USD | 80.97% |
| 2021 Q2 | -4.26 Million USD | 0.0% |
| 2021 Q1 | -4.26 Million USD | 97.27% |
| 2020 FY | -165.78 Million USD | -370.28% |
| 2020 Q4 | -156.06 Million USD | -2633.7% |
| 2020 Q3 | -5.7 Million USD | -108.66% |
| 2020 Q2 | -2.73 Million USD | -114.59% |
| 2020 Q1 | -1.27 Million USD | -102.17% |
| 2019 Q2 | 2.14 Million USD | 556.29% |
| 2019 FY | 61.34 Million USD | 275.51% |
| 2019 Q1 | -469 Thousand USD | -122.31% |
| 2019 Q4 | 58.87 Million USD | 7296.11% |
| 2019 Q3 | 796 Thousand USD | -62.8% |
| 2018 Q2 | 249 Thousand USD | 811.43% |
| 2018 Q1 | -35 Thousand USD | 99.68% |
| 2018 FY | 16.33 Million USD | 133.09% |
| 2018 Q4 | 2.1 Million USD | -85.01% |
| 2018 Q3 | 14.01 Million USD | 5530.12% |
| 2017 FY | 7 Million USD | 115.77% |
| 2017 Q2 | 13.73 Million USD | 956.46% |
| 2017 Q3 | 2.88 Million USD | -78.98% |
| 2017 Q4 | -10.91 Million USD | -478.0% |
| 2017 Q1 | 1.3 Million USD | 102.96% |
| 2016 Q3 | 630 Thousand USD | 274.03% |
| 2016 Q1 | -757 Thousand USD | 7.0% |
| 2016 FY | -44.45 Million USD | -1260.19% |
| 2016 Q2 | -362 Thousand USD | 52.18% |
| 2016 Q4 | -43.96 Million USD | -7078.1% |
| 2015 FY | -3.26 Million USD | -205.83% |
| 2015 Q1 | 629 Thousand USD | 158.35% |
| 2015 Q4 | -814 Thousand USD | 80.9% |
| 2015 Q3 | -4.26 Million USD | -418.54% |
| 2015 Q2 | 1.33 Million USD | 112.72% |
| 2014 Q3 | 5.1 Million USD | 5259.6% |
| 2014 Q1 | -426 Thousand USD | 50.98% |
| 2014 Q4 | -1.07 Million USD | -121.1% |
| 2014 Q2 | -99 Thousand USD | 76.76% |
| 2014 FY | 3.08 Million USD | 602.93% |
| 2013 Q1 | -721 Thousand USD | 89.74% |
| 2013 FY | -614 Thousand USD | 87.95% |
| 2013 Q4 | -869 Thousand USD | 12.4% |
| 2013 Q3 | -992 Thousand USD | -150.38% |
| 2013 Q2 | 1.96 Million USD | 373.09% |
| 2012 Q1 | 1.37 Million USD | 282.58% |
| 2012 FY | -5.09 Million USD | -161.93% |
| 2012 Q4 | -7.02 Million USD | -297.51% |
| 2012 Q3 | -1.76 Million USD | -175.91% |
| 2012 Q2 | 2.32 Million USD | 69.63% |
| 2011 Q2 | 3.27 Million USD | 73.68% |
| 2011 FY | 8.22 Million USD | -33.19% |
| 2011 Q4 | -752 Thousand USD | -119.73% |
| 2011 Q1 | 1.88 Million USD | -49.51% |
| 2011 Q3 | 3.81 Million USD | 16.22% |
| 2010 Q4 | 3.73 Million USD | 12.18% |
| 2010 FY | 12.31 Million USD | 23.96% |
| 2010 Q3 | 3.33 Million USD | 6.52% |
| 2010 Q1 | 2.11 Million USD | -27.26% |
| 2010 Q2 | 3.12 Million USD | 48.22% |
| 2009 FY | 9.93 Million USD | -8.79% |
| 2009 Q1 | 2.21 Million USD | 326.01% |
| 2009 Q4 | 2.9 Million USD | 51.78% |
| 2009 Q3 | 1.91 Million USD | -34.23% |
| 2009 Q2 | 2.9 Million USD | 31.48% |
| 2008 Q2 | 3.1 Million USD | 30.25% |
| 2008 FY | 10.88 Million USD | 219.31% |
| 2008 Q3 | 4.89 Million USD | 57.74% |
| 2008 Q1 | 2.38 Million USD | -18.66% |
| 2008 Q4 | 519 Thousand USD | -89.39% |
| 2007 Q3 | -16.4 Million USD | -768.5% |
| 2007 FY | -9.12 Million USD | -232.93% |
| 2007 Q2 | 2.45 Million USD | 29.29% |
| 2007 Q4 | 2.92 Million USD | 117.84% |
| 2007 Q1 | 1.89 Million USD | -6.87% |
| 2006 Q2 | 1.65 Million USD | 28.0% |
| 2006 Q4 | 2.03 Million USD | 8.4% |
| 2006 Q3 | 1.88 Million USD | 13.6% |
| 2006 Q1 | 1.29 Million USD | -22.39% |
| 2006 FY | 6.86 Million USD | 50.97% |
| 2005 Q4 | 1.66 Million USD | 53.55% |
| 2005 FY | 4.54 Million USD | 44.7% |
| 2005 Q3 | 1.08 Million USD | 4.73% |
| 2005 Q1 | 761 Thousand USD | -50.78% |
| 2005 Q2 | 1.03 Million USD | 36.14% |
| 2004 Q3 | 532 Thousand USD | 0.0% |
| 2004 Q4 | 1.54 Million USD | 190.6% |
| 2004 FY | 3.14 Million USD | 165.01% |
| 2003 FY | 1.18 Million USD | 17.54% |
| 2003 Q4 | 533 Thousand USD | 226.99% |
| 2003 Q3 | 163 Thousand USD | 0.0% |
| 2002 FY | 1 Million USD | 194.17% |
| 2001 FY | 343 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -63.32 Million USD | -191.125% |
| AtriCure, Inc. | -30.43 Million USD | -505.654% |
| Avinger, Inc. | -18.32 Million USD | -906.272% |
| Azenta, Inc. | -14.25 Million USD | -1193.042% |
| BioLife Solutions, Inc. | -66.42 Million USD | -177.521% |
| The Cooper Companies, Inc. | 294.2 Million USD | 162.661% |
| Daxor Corporation | 280.64 Thousand USD | 65788.783% |
| Ekso Bionics Holdings, Inc. | -15.19 Million USD | -1112.982% |
| Femasys Inc. | -14.24 Million USD | -1193.938% |
| GlucoTrack, Inc. | -7.09 Million USD | -2497.562% |
| Harvard Bioscience, Inc. | -3.41 Million USD | -5298.214% |
| Hologic, Inc. | 789.5 Million USD | 123.35% |
| ICU Medical, Inc. | -29.65 Million USD | -521.646% |
| Intuitive Surgical, Inc. | 1.79 Billion USD | 110.253% |
| KORU Medical Systems, Inc. | -13.74 Million USD | -1241.592% |
| LeMaitre Vascular, Inc. | 30.1 Million USD | 712.353% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -2666.579% |
| Innovative Eyewear, Inc. | -6.66 Million USD | -2666.579% |
| Masimo Corporation | 81.5 Million USD | 326.195% |
| Microbot Medical Inc. | -10.74 Million USD | -1616.471% |
| Meihua International Medical Technologies Co., Ltd. | 11.62 Million USD | 1685.741% |
| Merit Medical Systems, Inc. | 94.41 Million USD | 295.262% |
| Nephros, Inc. | -1.57 Million USD | -11604.698% |
| NovoCure Limited | -207.04 Million USD | 10.961% |
| NEXGEL, Inc. | -3.15 Million USD | -5739.373% |
| NEXGEL, Inc. | -3.15 Million USD | -5739.373% |
| Singular Genomics Systems, Inc. | -94.82 Million USD | -94.42% |
| OraSure Technologies, Inc. | 53.65 Million USD | 443.582% |
| Pro-Dex, Inc. | 2.12 Million USD | 8767.09% |
| Pulse Biosciences, Inc. | -42.21 Million USD | -336.742% |
| Predictive Oncology Inc. | -13.98 Million USD | -1218.288% |
| Precision Optics Corporation, Inc. | -2.95 Million USD | -6146.203% |
| QuidelOrtho Corporation | -10.1 Million USD | -1725.238% |
| Repligen Corporation | 41.57 Million USD | 543.392% |
| Sanara MedTech Inc. | -4.3 Million USD | -4184.001% |
| STAAR Surgical Company | 21.34 Million USD | 963.583% |
| Sharps Technology, Inc. | -9.84 Million USD | -1773.154% |
| Utah Medical Products, Inc. | 16.63 Million USD | 1208.2% |
| DENTSPLY SIRONA Inc. | -132 Million USD | -39.658% |
| Jin Medical International Ltd. | 2.87 Million USD | 6504.943% |